1998
DOI: 10.1590/s0037-86821998000600001
|View full text |Cite
|
Sign up to set email alerts
|

Tratamento da leishmaniose mucosa com sulfato de aminosidine: resultados de dois anos de acompanhamento

Abstract: In 1996, 20 of 21 patients with mucosal leishmaniasis, treated in 1994 with aminosidine sulfate, 16mg/kg/day salt, by intramuscular injection for 20 days, were clinically evaluated. One patient died due to disease not related to mucosal leishmaniasis. Seven of 14 patients (66.7% N = 21) who achieved complete remission three months after treatment remained clinically cured 24 months later and seven relapsed in the same period (50% N = 14). Sorological follow-up showed poor correlation with the results of clinic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0
1

Year Published

2005
2005
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(5 citation statements)
references
References 14 publications
(5 reference statements)
0
4
0
1
Order By: Relevance
“…In the Old World, failure of this drug is approximately 13%, and this drug is considered as satisfactory for the treatment of cutaneous leishmaniasis. In ML, the cure rate ranges from 30 to 90% with antimonials, depending on the country in which the study was carried out and the dosage used [81][82][83].…”
Section: First-line Drugsmentioning
confidence: 99%
See 1 more Smart Citation
“…In the Old World, failure of this drug is approximately 13%, and this drug is considered as satisfactory for the treatment of cutaneous leishmaniasis. In ML, the cure rate ranges from 30 to 90% with antimonials, depending on the country in which the study was carried out and the dosage used [81][82][83].…”
Section: First-line Drugsmentioning
confidence: 99%
“…In Peru, patients infected with L. (V.) guyanensis were found to be much more responsive to Sb V therapy than patients infected with L. (V.) braziliensis [119]. On the other hand, in Brazil, failure of antimonial therapy was higher in patients infected with L. (V.) guyanensis (73.7%) than in those infected with L. (V.) braziliensis (49.2%) [82]. This difference could be explained by the differences between the strains of Leishmania, even though the species were the same.…”
Section: Parasite Factorsmentioning
confidence: 99%
“…[18][19][20][21][22] O pequeno número de casos observados de LM dificulta obter conclusões sobre a eficácia de novas drogas. 23 Casos de LM refratários ao tratamento com Sb tiveram boa resposta terapêutica quando se associou pentoxifilina ao NMG, tendo como possível explicação a imunomodulação mediante bloqueio do TNFalfa causada pela pentoxifilina. 24,25 O tratamento com Sb tem ainda como desvantagem depender de múltiplas injeções.…”
Section: Treatment Of American Cutaneous Leishmaniasis *unclassified
“…The natural history of ML consists in the progressive destruction of the nasal septa and soft and hard palates, eventually causing severe facial disfiguration and respiratory disturbances that do not heal spontaneously [6]. Moreover, 22–50% of the individuals with ML are unresponsive to the current antimonial therapy and have an associated increase in morbidity and mortality [7].…”
Section: Introductionmentioning
confidence: 99%